Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.
about
Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseasesU12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathwaysNoninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis
P2860
Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Ursodeoxycholic acid therapy i ...... follow-up case-control study.
@en
Ursodeoxycholic acid therapy i ...... follow-up case-control study.
@nl
type
label
Ursodeoxycholic acid therapy i ...... follow-up case-control study.
@en
Ursodeoxycholic acid therapy i ...... follow-up case-control study.
@nl
prefLabel
Ursodeoxycholic acid therapy i ...... follow-up case-control study.
@en
Ursodeoxycholic acid therapy i ...... follow-up case-control study.
@nl
P2093
P2860
P1476
Ursodeoxycholic acid therapy i ...... follow-up case-control study.
@en
P2093
A Schweiger-Kabesch
C Glasmacher
P2860
P304
P356
10.1111/J.1365-2036.2012.05177.X
P407
P577
2012-06-07T00:00:00Z